Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib + R-CHOP in DLBCL
NCT04546620Phase 2Active, not recruiting
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Oct 2021
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of acalabrutinib in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoint: Efficacy at 4.5 years. Started Oct 2021; status: active, not recruiting.
02
Drugs
acalabrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04546620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04546620.